Decision science – changing the interpretation of early clinical trials
Phase 1, first-in-human clinical trials are amongst the most complex and challenging during drug development and involve the organisation, gathering and interpretation of large amounts of data (~10,000 data points per patient). Adaptive changes are often needed regarding the dose, schedule, patient population, the combination of drugs and the deployment of potential predictive biomarkers. This drives the need for near real-time access to emerging trial data to support timely and effective decision-making.
REACT – REal time Analytics for Clinical Trials
We explore new ways to conduct and interpret clinical trials. Our research platform facilitates research into new data-models, tools and techniques to collect, curate, analyse, interpret and visualise data. REACT, our advanced analytics system enables:
- fast, intuitive and powerful drill-down from all data points across the clinical trial
- an integrated view of all data, over time for an individual, selected patient
- flexible exploration of clinical data – safety, laboratory measurements, efficacy, pharmacokinetics and genomics
- near real-time decision making and hypothesis generation
- integration of genomic and clinical data in real-time and a greater understanding of gene signatures associated with response
“While it used to take me a day to prepare data for discussion at a meeting, now it takes an hour. REACT enables us to focus on interpreting the findings. It makes time for science!” Sponsor
The digital ECMT brought together clinicians, technology and genomic experts. We are now able to create a link between our REACT Genomic Profile and CBioPortal (open source tool for genomic analysis) to perform more in-depth analysis for patients of interest. An additional enhancement is the ability to track genetic changes in the tumour over time using ct DNA (circulating tumour DNA) visualisations, which could contribute to the earlier detection of disease progression for some patients.
“The integration of genomic and clinical data has significantly improved the ability to interpret responder populations in an ongoing clinical trial and the delivery of platform trials” Clinical Director